Camden National Bank reduced its position in Becton Dickinson and Co (NYSE:BDX) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,028 shares of the medical instruments supplier’s stock after selling 727 shares during the quarter. Becton Dickinson and makes up about 2.5% of Camden National Bank’s portfolio, making the stock its 6th largest position. Camden National Bank’s holdings in Becton Dickinson and were worth $11,643,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of BDX. Whittier Trust Co. boosted its stake in Becton Dickinson and by 0.6% during the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after acquiring an additional 40 shares in the last quarter. ProVise Management Group LLC raised its holdings in Becton Dickinson and by 2.2% during the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock worth $479,000 after buying an additional 41 shares during the last quarter. Pitcairn Co. raised its holdings in Becton Dickinson and by 1.3% during the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock worth $813,000 after buying an additional 41 shares during the last quarter. Ropes Wealth Advisors LLC raised its holdings in Becton Dickinson and by 0.6% during the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after buying an additional 43 shares during the last quarter. Finally, Armor Investment Advisors LLC raised its holdings in Becton Dickinson and by 0.5% during the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock worth $2,335,000 after buying an additional 44 shares during the last quarter. 84.21% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on BDX shares. Morgan Stanley upped their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co upped their price objective on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Raymond James upped their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a report on Friday, June 28th. Finally, Piper Jaffray Companies lowered their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $266.55.
Shares of BDX stock traded up $4.38 on Friday, hitting $252.92. The stock had a trading volume of 55,372 shares, compared to its average volume of 1,005,967. The business has a 50 day moving average of $253.65 and a 200 day moving average of $245.78. The stock has a market cap of $66.00 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.56 and a beta of 1.12. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $264.74.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.91 earnings per share. As a group, research analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a $0.77 dividend. The ex-dividend date was Friday, September 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.22%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
In other news, Director Claire Fraser sold 1,429 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 1,717 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $249.88, for a total transaction of $429,043.96. Following the completion of the sale, the executive vice president now owns 19,966 shares of the company’s stock, valued at approximately $4,989,104.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,249 shares of company stock valued at $9,616,803. 0.12% of the stock is currently owned by corporate insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: What is the Stochastic Momentum Index (SMI)?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.